Fiduciary Trust Co Trims Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Fiduciary Trust Co lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 21.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,421 shares of the medical equipment provider’s stock after selling 2,012 shares during the quarter. Fiduciary Trust Co’s holdings in Zimmer Biomet were worth $903,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Primecap Management Co. CA lifted its stake in shares of Zimmer Biomet by 10.5% during the 4th quarter. Primecap Management Co. CA now owns 5,086,578 shares of the medical equipment provider’s stock worth $619,037,000 after purchasing an additional 484,151 shares during the period. American Century Companies Inc. lifted its stake in shares of Zimmer Biomet by 21.2% during the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock worth $545,809,000 after purchasing an additional 852,186 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Zimmer Biomet by 3.9% during the 4th quarter. Victory Capital Management Inc. now owns 3,199,302 shares of the medical equipment provider’s stock worth $389,355,000 after buying an additional 118,839 shares during the last quarter. Van ECK Associates Corp increased its holdings in shares of Zimmer Biomet by 23.7% during the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock worth $345,452,000 after buying an additional 543,344 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Zimmer Biomet by 16.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,760,021 shares of the medical equipment provider’s stock worth $335,895,000 after buying an additional 386,019 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $114.43 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $147.50. The company’s 50-day simple moving average is $122.57 and its 200-day simple moving average is $121.80. The stock has a market capitalization of $23.54 billion, a price-to-earnings ratio of 24.77, a PEG ratio of 2.08 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the company posted $1.89 earnings per share. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Analyst Ratings Changes

ZBH has been the subject of a number of research analyst reports. Truist Financial dropped their price objective on Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a report on Friday, May 3rd. Barclays upped their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a report on Monday, February 12th. StockNews.com downgraded Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a report on Monday, February 19th. Oppenheimer upped their price objective on Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Finally, JPMorgan Chase & Co. increased their price target on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $134.06.

Check Out Our Latest Analysis on ZBH

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.